Navigation Links
Exemestane plus everolimus increased progression-free survival
Date:12/7/2011

SAN ANTONIO Everolimus in combination with exemestane has shown promise for the treatment of breast cancer.

"For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D., FACP, professor of medicine, chair of the department of breast medical oncology and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center in Houston.

Hortobagyi presented findings from Breast Cancer Trials of Oral Everolimus (BOLERO-2), a phase 3 clinical trial, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

BOLERO-2 researchers enrolled 724 postmenopausal patients with HR-positive metastatic breast cancer and evidence of progressive disease while receiving anastrozole or letrozole. They randomly assigned patients to treatment with exemestane plus everolimus or with exemestane plus placebo.

Results revealed a median progression-free interval of 3.2 months for 239 patients treated with exemestane plus placebo. Among the 485 patients treated with exemestane plus everolimus, researchers found a median progression-free interval of 7.4 months, "a highly significant difference," Hortobagyi said.

Clinical benefit rates, which include complete response, partial response, or stable disease exceeding six months, were 25.5 percent among patients treated with exemestane and placebo and 50.5 percent among those treated with exemestane and everolimus.

"The original hypothesis predicted this increased benefit from the combination, based on compelling preclinical experiments and preliminary results from earlier, smaller clinical trials. These results establish a new standard of care for this group of patients," Hortobagyi said.

He continued, "These results highlight the progress being made in understanding the evolving mechanisms of resistance to standard therapies."

Researchers were not yet able to measure survival analysis in BOLERO-2. However, treatment was well tolerated, with oral mucositis, fatigue, pneumonitis and hyperglycemia being the most common side effects.


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
210-582-7021
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
2. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
3. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
4. Everolimus improves progression-free survival for patients with rare pancreatic cancer
5. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
6. An important reduction in risk of stent thrombosis with everolimus-eluting stent
7. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
8. Migraine Linked to Increased Heart Attack Risk
9. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
10. Increased HAART coverage associated with 50 percent drop
11. RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... The Price Agency in Birmingham, AL ... assist the people of their local community. The agency pledges to select a ... Their desire is to bring awareness to important local causes with fundraising and ...
(Date:5/6/2016)... ... May 06, 2016 , ... The joy associated with Mother’s Day is mixed with ... neonatal intensive care units (NICUs) across the country. For the first time ever, the ... honor these women who spend their Mother’s Day beside a crib surrounded by lifesaving equipment ...
(Date:5/6/2016)... ... ... US Sports Camps has collaborated with State Rugby Organization (SRO), Rugby Oregon, ... Employing world-class rugby figures, including former Team USA players and college coaches, this program ... match play, fitness and more. , “US Sports Camps is honored to be working ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ... offering for global clients of Coupa ( Coupa Software ) and other Cloud ... is a key component in the suite of innovative implementation services offered by ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... International plc (NASDAQ: ENDP ) (TSX: ENL) today ... president of Allergan, Inc. and current CEO of Chase Pharmaceuticals ... TPG Capital, to its Board of Directors. The appointments are ... recently embarked on a search for new Board members who ... and Todd are experienced leaders, and we are extremely pleased ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
Breaking Medicine Technology: